Meet the Team
Management of the Provis Infusion Clinic
Provis Infusion Clinic was established by a group of health care professionals who are interested in the changing landscape of healthcare delivery in Canada. Our directors have many years of experience in designing, founding and operating health care companies and freestanding clinics in Canada.
Graham Vincent, BPHE, MBA
President, Provis Infusion Clinic
Graham has over 25 years of business management experience in providing patient oriented services in the healthcare industry. He has successfully built and lead several leading healthcare organizations.
Director of Pharmaceutical Services, Provis Infusion Clinic
Ostap has been a pharmacist for 25 years and has been in involved with oncology medication preparation for over 25 years. He has previously worked at Toronto General Hospital (UHN). He also works at the Sunnybrook Regional Cancer Program on an occasional basis and is up to date on new drug developments. He also has worked in the pharmaceutical industry for a major pharmaceutical company in business and product development.
Our Dedicated Staff
Our physician staff consists of three Physicians from emergency medicine and oncology. All infusions are supervised by on-site physician.
Our pharmaceutical team consists of three Pharmacists and three Pharmacy Technicians. Your medications are always mixed on site by a Pharmacy Technician who is supervised by the Pharmacist. All of our medication compounding is done on site to make things as seamless and flexible as possible.
Our helpful and friendly office staff provide efficient and seamless administrative services from first patient contact to completion of treatment. They take pride in anticipating the needs of our patients and referring physicians while ensuring smooth business operations at the clinic.
We recognize the invaluable contribution an experienced nurse can make to the patient experience in intravenous therapies. Our nurses are highly trained and certified in their specialty with many years of experience in patient care. Their compassion and respect for each patient’s individuality has a lasting, positive effect on the well being of our patients.
Why Choose Provis?
- Infusion Services Since 2005
- Over 11,000+ Infusions To Date
- Most Comprehensive Oncology Drug Formulary in Canada
- Onsite Medication Compounding Facility
- Experienced Pharmacists On-Site
- Experienced Oncology Trained Nurses
- Supervising Physician On-Site
12 Year Anniversary!The Provis Infusion Clinic is please to announce that August 2017 marks the 12 anniversary of the Provis Infusion Clinic. We are looking forward to the next 12 years of providing high quality infusion services.
Sunnybrook Health Sciences Centre PartnershipProvis has been chosen as the preferred provider by Sunnybrook Health Sciences Centre for private paid infusions originating from the hospital. For further details please contact Provis.
Expanded Indications for OPDIVO™ and KEYTRUDA™OPDIVO™ is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumour aberrations should have disease progression on a therapy for these aberrations prior to receiving OPDIVO™. KEYTRUDA™ has received NOC with Conditions for use in the treatment of patients with: Metastatic NSCLC whose tumours express PD-L1 and who have a disease progression on or after platinum-containing chemotherapy. patients with EGFR or ALK genomic tumour aberrations should have disease progression on authorized therapy for these aberrations prior to receiving KEYTRUDA™.
Kyprolis™ (Carfilzomib) receives Health Canada approval.Health Canada has approved Kyprolis™ (carfilzomib) in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy.
Opdivo™ (Nivolumab) receives Health Canada approval.Opdivo™ is the first anti PD-1 (programmed death-1) approved to treat previously untreated cases of BRAF V600 wild-type unresectable or metastatic melanoma in adults. The approval was made under the Health Canada Priority Review process, after having met the criteria of substantial evidence of clinical effectiveness providing an improved benefit/risk profile over existing therapies. Provis is also able to provide Opdivo™ for other indications if required.
Keytruda™ (Pembrolizumab) now offered at ProvisAUTHORIZATION WITH CONDITIONS OF KEYTRUDA™ for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab therapy and, if BRAF V600 mutation positive, following a BRAF or MEK inhibitor
Update – Patient Support Programs
Keytruda®, Perjeta®, Herceptin®, Avastin®,Jevtana®, Rituxan®, Abraxane®, Treanda® Kadcyla® and Kyprolis® Patients: Provis participates in the Roche Patient Assistance Program, the Treanda Support Program, the Merck Care Oncology, Kyprolis (Victory) and Celgene Abraxane® Access Program . These program offers financial assistance to qualified patients receiving Kyprolis®, Keytruda®, Perjeta®, Herceptin®, Avastin®, Rituxan®, Abraxane®,Treanda® and Kadcyla® Read More >>
Non-Muscle Invasive Bladder CancerProvis works with the University Urology Associates (UUA), in providing the compounded MMC for electronically stimulated Mitomycin-C (EMDA MMC) to treat non-muscle invasive bladder cancer.
The Ride to Conquer CancerThe Provis Pelotons Cycling Team participate in the 2015 Ride to Conquer Cancer. The ride is over 220km's from Toronto to Niagara Falls. The team raised close to $13,000 for cancer research. Way to go Graham, Deb, Steve, Samantha and Dave.